JP7797203B2 - 抗ｇａｌ９免疫阻害性結合分子 - Google Patents

抗ｇａｌ９免疫阻害性結合分子

Info

Publication number
JP7797203B2
JP7797203B2 JP2021570997A JP2021570997A JP7797203B2 JP 7797203 B2 JP7797203 B2 JP 7797203B2 JP 2021570997 A JP2021570997 A JP 2021570997A JP 2021570997 A JP2021570997 A JP 2021570997A JP 7797203 B2 JP7797203 B2 JP 7797203B2
Authority
JP
Japan
Prior art keywords
gal9
antigen
binding molecule
immune cells
control agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021570997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534433A (ja
JP2022534433A5 (https=
Inventor
ミッシェル・ワイクス
ディリープ・ケー・プルックナット
Original Assignee
ザ・カウンシル・オブ・ザ・クィーンズランド・インスティテュート・オブ・メディカル・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・カウンシル・オブ・ザ・クィーンズランド・インスティテュート・オブ・メディカル・リサーチ filed Critical ザ・カウンシル・オブ・ザ・クィーンズランド・インスティテュート・オブ・メディカル・リサーチ
Publication of JP2022534433A publication Critical patent/JP2022534433A/ja
Publication of JP2022534433A5 publication Critical patent/JP2022534433A5/ja
Priority to JP2025107319A priority Critical patent/JP2025146842A/ja
Application granted granted Critical
Publication of JP7797203B2 publication Critical patent/JP7797203B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021570997A 2019-05-31 2020-05-29 抗ｇａｌ９免疫阻害性結合分子 Active JP7797203B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025107319A JP2025146842A (ja) 2019-05-31 2025-06-25 抗ｇａｌ９免疫阻害性結合分子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962855590P 2019-05-31 2019-05-31
US62/855,590 2019-05-31
US201962900105P 2019-09-13 2019-09-13
US62/900,105 2019-09-13
PCT/AU2020/050546 WO2020237320A1 (en) 2019-05-31 2020-05-29 Anti-gal9 immune-inhibiting binding molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025107319A Division JP2025146842A (ja) 2019-05-31 2025-06-25 抗ｇａｌ９免疫阻害性結合分子

Publications (3)

Publication Number Publication Date
JP2022534433A JP2022534433A (ja) 2022-07-29
JP2022534433A5 JP2022534433A5 (https=) 2023-06-07
JP7797203B2 true JP7797203B2 (ja) 2026-01-13

Family

ID=73552467

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570997A Active JP7797203B2 (ja) 2019-05-31 2020-05-29 抗ｇａｌ９免疫阻害性結合分子
JP2025107319A Withdrawn JP2025146842A (ja) 2019-05-31 2025-06-25 抗ｇａｌ９免疫阻害性結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025107319A Withdrawn JP2025146842A (ja) 2019-05-31 2025-06-25 抗ｇａｌ９免疫阻害性結合分子

Country Status (10)

Country Link
US (1) US20220227873A1 (https=)
EP (1) EP3976102A4 (https=)
JP (2) JP7797203B2 (https=)
KR (1) KR20220030934A (https=)
CN (1) CN114025797A (https=)
AU (1) AU2020285369A1 (https=)
CA (1) CA3141640A1 (https=)
IL (1) IL288561A (https=)
SG (1) SG11202113132YA (https=)
WO (1) WO2020237320A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220235135A1 (en) * 2019-05-31 2022-07-28 The Council Of The Queensland Institute Of Medical Research Activating anti-gal9 binding molecules
CR20240489A (es) * 2022-05-13 2025-01-07 Exelixis Inc Agentes aglutinantes 5t4 y usos de los mismos
PE20252168A1 (es) * 2023-01-27 2025-09-04 Exelixis Inc Agentes de union nkg2a y usos de estos
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515766A (ja) 2009-01-26 2012-07-12 国立大学法人 岡山大学 免疫抑制剤および自己免疫疾患の予防および治療剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511085A1 (en) * 1993-03-05 1994-09-15 Universite Catholique De Louvain Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2003033709A2 (en) * 2001-10-17 2003-04-24 Bayer Healthcare Ag Regulation of human serine/threonine protein kinase
AR080795A1 (es) * 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
WO2016008005A1 (en) * 2014-07-14 2016-01-21 The Council Of The Queensland Institute Of Medical Research Galectin immunotherapy
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515766A (ja) 2009-01-26 2012-07-12 国立大学法人 岡山大学 免疫抑制剤および自己免疫疾患の予防および治療剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Arch. Dermatol. Res.，2016年，Vol. 308，p. 553-561

Also Published As

Publication number Publication date
JP2025146842A (ja) 2025-10-03
JP2022534433A (ja) 2022-07-29
US20220227873A1 (en) 2022-07-21
EP3976102A4 (en) 2023-07-12
CA3141640A1 (en) 2020-12-03
EP3976102A1 (en) 2022-04-06
WO2020237320A1 (en) 2020-12-03
CN114025797A (zh) 2022-02-08
SG11202113132YA (en) 2021-12-30
AU2020285369A1 (en) 2021-12-23
IL288561A (en) 2022-02-01
KR20220030934A (ko) 2022-03-11

Similar Documents

Publication Publication Date Title
TWI718206B (zh) Pd-l1抗體、其抗原結合片段及其醫藥用途
JP7303126B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
JP7240335B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
JP7352973B2 (ja) 二重特異性抗体及びその使用
JP7797203B2 (ja) 抗ｇａｌ９免疫阻害性結合分子
JP7257971B2 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
JP2020536543A (ja) 抗ｃｄ３８抗体および使用方法
CN110167966A (zh) 程序性细胞死亡(pd-1)的单结构域抗体
US12006367B2 (en) CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
EP4228693A1 (en) Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
TW201833141A (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
JP2018501297A (ja) Ｃｄ３／ｃｄ３８ ｔ細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
WO2015197582A1 (en) Monomeric multispecific antigen binding proteins
EP3752188A1 (en) Therapeutic molecules that bind to lag3 and pd1
US20220235135A1 (en) Activating anti-gal9 binding molecules
CN117715940A (zh) 抗trem-1抗体
WO2024078558A1 (zh) 抗cd100抗体及其用途
WO2024160269A9 (zh) 针对muc17和cd3的双特异性抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250625

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251224

R150 Certificate of patent or registration of utility model

Ref document number: 7797203

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150